Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MAIA Biotechnology, Inc. ( (MAIA) ) has provided an announcement.
On May 21, 2026, MAIA Biotechnology, Inc. held its 2026 Annual Meeting of stockholders, with a quorum achieved as approximately 61.88% of the 60,671,491 eligible common shares were represented in person or by proxy. Shareholders re-elected Class I directors Louie Ngar Yee and Steven Chaouki to three-year terms expiring in 2029, maintaining continuity on the company’s board.
At the same meeting on May 21, 2026, stockholders also ratified the appointment of Grant Thornton LLP as MAIA Biotechnology’s independent registered public accounting firm for the fiscal year ending December 31, 2026. These voting outcomes reinforced the existing leadership and auditor relationships, signaling shareholder support for the company’s current governance and financial oversight structure.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a publicly traded life sciences company listed on the NYSE American under the ticker MAIA. The company operates in the biotechnology sector, focusing on the development of innovative therapies and related technologies for medical applications, targeting investors and stakeholders in the healthcare and biotech markets.
Average Trading Volume: 876,571
Technical Sentiment Signal: Sell
Current Market Cap: $78.43M
Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.